2.040USD-3.77%Mkt Cap: 3.67M USDP/E: 0.05Last update: 2026-06-01
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap3.67M USD
Enterprise Value-7.34M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.96M USD
Revenue/Share—
Last Price2.040 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.05
P/E (Forward)-0.73
PEG—
EV/EBITDA0.67
EV/Revenue—
P/S—
P/B0.31
EPS (TTM)38.89
EPS (Forward)-2.83
52W Range
1.9700% of range80.36
52W High80.36 USD
52W Low1.970 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-199.00%
ROA-137.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.19M USD
CapEx (TTM)3.00K USD
FCF Margin—
FCF Yield-207.65%
Net Debt-10.99M USD
Net Debt/EBITDA1.01
Balance Sheet
Debt/Equity0.01
Current Ratio14.21
Quick Ratio13.91
Book Value/Sh6.653 USD
Cash/Share6.239 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateJan 26, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)25.00 USD
Target Range10.00 USD – 40.00 USD
# Analysts2
Ownership
Shares Out.1.77M
Float1.77M
Insiders0.46%
Institutions1.59%
Short Interest
Short Ratio2.8d
Short % Float6.44%
Short % Out.6.44%
Shares Short114.07K
Short (prev mo.)134.38K
Technical
SMA 502.326 (-12.3%)
SMA 20023.46 (-91.3%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)37.38K
Avg Vol (10d)32.05K
Technical Indicators
RSI (14)42.4
MACD-0.0829
MACD Signal-0.0859
MACD Hist.+0.0031
BB Upper2.380 USD
BB Middle2.190 USD
BB Lower2.000 USD
BB Width17.37%
ATR (14)0.1364 USD
Vol Ratio (20d)0.54x